心臓腫瘍市場は、2021 年の市場価値が 7 億 8,334 万ドルに達し、予測期間中は 6.31% という大幅な CAGR を記録する見込みです。心臓腫瘍は、癌性（悪性）または非癌性の心臓の異常な発達です。原発性（心臓自体から生じる）および続発性心臓腫瘍は、この疾患のさらなる分類です。原発性心臓腫瘍は 3000 人に約 1 人にしか発生しないため、非常にまれです。主な心臓腫瘍の 20 〜 30 倍の頻度で起こる、後続性心臓腫瘍は通常、肺がん、乳がん、黒色腫、腎細胞がん、またはリンパ腫の患者に発生します。
市場の推進要因としては、心臓腫瘍の発生率の上昇、がん研究プロジェクトの数と資金の増加、戦略的イニシアチブの増加などがあります。しかし、心臓腫瘍についての意識を高めるための公的および民間組織による取り組みの拡大が、市場参加者にとって有益な見通しを示しています。しかし、人々の認識の不足と必要なスキルを持つ放射線科医の不足によって心臓腫瘍市場の発展が妨げられr可能性があります。心臓腫瘍市場を推進する主な要因の 1 つは、心臓肉腫、不整脈、胸部不快感、脳卒中、心嚢液貯留などの心臓腫瘍の有病率の増加です。さらに、無症候性キャリアの増加と心臓肉腫の発生率の上昇が、特に COVID-19 のパンデミック時に、市場の拡大をさらに加速させています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING PREVALENCE OF CARDIAC TUMORS
4.2.2 INCREASING NUMBER OF CANCER RESEARCH AND FUNDING
4.2.3 RISING NUMBER OF STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS AMONG PEOPLE
4.3.2 LACK OF SKILLED RADIOLOGISTS
4.4 OPPORTUNITIES
4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING HEART TUMOR
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE HEART TUMOR MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON KEY PLAYERS
5.3.4 IMPACT ON REGION
6 GLOBAL HEART TUMOR MARKET, TUMOR TYPE
6.1 OVERVIEW
6.2 PRIMARY TUMOR
6.3 SECONDARY TUMOR
7 GLOBAL HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW
7.2 DIAGNOSIS
7.2.1 CT SCAN
7.2.2 MRI SCAN
7.2.3 NUCLEAR IMAGING
7.2.4 ECHOCARDIOGRAPHY
7.2.5 OTHERS
7.3 TREATMENT
7.3.1 COST PER PROCEDURE
7.3.2 SURGERY
7.3.3 CHEMOTHERAPY
7.3.4 RADIOTHERAPY
7.3.5 OTHERS
8 GLOBAL HEART TUMOR MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 SOUTH KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL HEART TUMOR MARKET
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL HEART TUMOR MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
9.6.2 PARTERSHIP/AGREEMENT
9.6.3 MERGER /ACQUISTION
9.6.4 EXPANSION /INVESTMENT
9.7 FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 R&D EXPENDITURE (USD MILLION), 2021
10 COMPANY PROFILE
10.1 KONINKLIJKE PHILIPS N.V.
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS/SERVICES OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 FUJIFILM CORPORATION
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 GE HEALTHCARE
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 SIEMENS
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 AMNEAL PHARMACEUTICALS LLC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 SHIMADZU CORPORATION
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 TOMTEC IMAGING SYSTEMS GMBH
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIES
10.8 TOSHIBA CORPORATION
10.8.1 COMPANY OVERVIEWS
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS TOSHIBA CORPORATION OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 BOSTON SCIENTIFIC CORPORATION
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
?
